^^^ in response to your earlier post Gareth, forgot to hit reply.

First 31 Last

Share
Profile

Follow
whirlswirl

176 Posts.

40

02/09/24

19:36

Post #: 75494807
Share

Originally posted by whirlswirl: ↑

I'm interested in the article you posted as it doesn't relate to Micro-X's CT scanner - the scanner doesn't use AI to reconstruct a 3D image of the brain nor perform an initial diagnosis. they just use an image reconstruction algorithm similar in general terms to the ones used in conventional CT machines today, but different in that it takes into account the unique configuration of the emission and detector. The image is then sent to a radiologist, who can look at the image and know whether it is a stroke or a bleed - and give advice so that clinical care can be administered straight away if appropriate. The strength of this is that they've miniaturised the CT which is the clinical standard, if it meets this standard there's no desperate need for an overlaid AI classification model to decipher where the clot or the bleed is, it'll be to the standard that radiologists use already to tell the difference with the human eye. You can add a model over the top to augment our ability and make it better, but we aren't relying on any model to perform a diagnosis.

EMvision on the other hand do use an AI classification model to determine whether there is a thrombus or a haemorrhage from my knowledge.

Expand

^^^ in response to your earlier post Gareth, forgot to hit reply.

Last edited by whirlswirl: 02/09/24

MX1 Price at posting: 6.0¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 24 more messages in this thread...

First 31 Last

Add MX1 (ASX) to my watchlist

(20min delay)
Last 7.0¢		Change 0.010(16.7%)		Mkt cap ! $40.71M

Open	High	Low	Value	Volume
6.9¢	8.2¢	6.9¢	$53.43K	730.2K

Buyers (Bids)

No.	Vol.	Price($)
1	3731	6.7¢

Sellers (Offers)

Price($)	Vol.	No.
7.5¢	150000	1

View Market Depth

No.	Vol.	Price($)
1	3731	0.067
1	75757	0.066
1	6460	0.065
1	92000	0.062
2	5320	0.060

Price($)	Vol.	No.
0.075	150000	1
0.080	50000	1
0.083	150000	1
0.085	30000	1
0.090	10000	1

Last trade - 14.49pm 07/10/2024 (20 minute delay)

MX1 (ASX) Chart

^^^ in response to your earlier post Gareth, forgot to hit reply.

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

^^^ in response to your earlier post Gareth, forgot to hit reply.

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News